Bazhu Decoction, a Traditional Chinese Medical Formula, Ameliorates Cognitive Deficits in the 5xFAD Mouse Model of Alzheimer's Disease

• Main Authors: Axiang Peng (Author), Yuehong Gao (Author), Xiaomei Zhuang (Author), Yaoqi Lin (Author), Wencan He (Author), Yannan Wang (Author), Wenfan Chen (Author), Tingting Chen (Author), Xiaoqing Huang (Author), Renzhi Yang (Author), Yuanpeng Huang (Author), Shengyan Xi (Author), Xian Zhang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2019-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1663-9812; 10.3389/fphar.2019.01391
• Keywords: Bazhu decoction; Alzheimer's disease (AD); 5xFAD mice; β-amyloid (Aβ); traditional Chinese medicine (TCM); Therapeutics. Pharmacology; RM1-950
• Source: Frontiers in Pharmacology, Vol 10 (2019)

Alzheimer's disease (AD) is the most common neurodegenerative disorder associated with aging. There are currently no effective treatments for AD. Bazhu decoction (BZD), a traditional Chinese medicine (TCM) formula, has been employed clinically to alleviate AD. However, the underlying molecular mechanisms are still unclear. Here we found that middle- and high-doses of BZD ameliorated the behavioral aspects of 5xFAD transgenic mice in elevated plus maze, Y maze and Morris water maze tests. Moreover, BZD reduced the protein levels of BACE1 and PS1, resulting in a reduction of Aβ plaques. We also identified a beneficial effect of BZD on oxidative stress by attenuating MDA levels and SOD activity in the brains of 5xFAD mice. Together, these results indicate that BZD produces a dose-dependent positive effect on 5xFAD transgenic mouse model by decreasing APP processing and Aβ plaques, and by ameliorating oxidative damage. BZD may play a protective role in the cognitive and anxiety impairments and may be a complementary therapeutic option for AD.